<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Clusterin (CLU / Apolipoprotein J)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[CLU](/entities/clu)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P10909" target="_blank">P10909</a></td>
</tr>
<tr>
<td class="label">PDB Structures</td>
<td><a href="https://www.rcsb.org/structure/6RDM" target="_blank">6RDM</a>, <a href="https://www.rcsb.org/structure/9IFM" target="_blank">9IFM</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>75–80 kDa (glycosylated heterodimer)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Secreted (sCLU), cytoplasmic/nuclear (nCLU/iCLU)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Apolipoprotein / extracellular chaperone</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy), Age-Related Macular Degeneration</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<t
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Clusterin (CLU / Apolipoprotein J)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[CLU](/entities/clu)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P10909" target="_blank">P10909</a></td>
</tr>
<tr>
<td class="label">PDB Structures</td>
<td><a href="https://www.rcsb.org/structure/6RDM" target="_blank">6RDM</a>, <a href="https://www.rcsb.org/structure/9IFM" target="_blank">9IFM</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>75–80 kDa (glycosylated heterodimer)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Secreted (sCLU), cytoplasmic/nuclear (nCLU/iCLU)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Apolipoprotein / extracellular chaperone</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy), Age-Related Macular Degeneration</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">160 edges</a></td>
</tr>
</table>
Knowledge graph relationships for CLUSTERIN (283 total edges in KG)
Clusterin (Clu Apolipoprotein J) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Clusterin (CLU), also known as Apolipoprotein J (ApoJ), complement lysis inhibitor (CLI), testosterone-repressed prostate message 2 (TRPM-2), or sulfated glycoprotein 2 (SGP-2), is a 75–80 kDa secreted heterodimeric glycoprotein encoded by the [clu](/genes/clu) gene on chromosome 8p21.1. [Clusterin is one of the most abundant glycoproteins in cerebrospinal fluid and is expressed widely across tissues, with particularly high levels in the brain, liver, and tes ([May & Bhatt, 2023](https://doi.org/10.3389/fnagi.2023.1167886)).
The CLU gene is the third most significant genetic risk locus for late-onset [alzheimers](/diseases/alzheimers-disease) (LOAD), after [apoe](/proteins/apoe-protein) ([Harold et al., 2009](https://doi.org/10.1038/ng.440); [Lambert et al., 2009](https://doi.org/10.1038/ng.439)). CLU variants may account for approximately 9% of late-onset AD attributable risk. Functionally, clusterin acts as an extracellular molecular chaperone that prevents aggregation of misfolded proteins, modulates complement activation, regulates lipid transport, and influences [Amyloid-Beta](/proteins/amyloid-beta) clearance. The complex biology of clusterin — with distinct isoforms exerting protective versus cytotoxic effects — has made it one of the most intensively studied proteins in neurodegeneration ([Nuutinen et al., 2009](https://doi.org/10.1016/j.brainresrev.2009.05.007)).
The CLU gene spans approximately 18 kb and contains 9 exons. The primary translation product is a 449-amino acid precursor polypeptide that undergoes extensive post-translational processing:
Clusterin has a distinctive three-domain architecture ([Patel et al., 2025](https://doi.org/10.1038/s41594-025-01631-4)):
| Isoform | Designation | Localization | Function |
|---|---|---|---|
| Secreted clusterin | sCLU | Extracellular, plasma, CSF | Chaperone, complement inhibitor, lipid transport — protective |
| Nuclear clusterin | nCLU | Nucleus | Pro-apoptotic signaling — cytotoxic |
| Intracellular clusterin | iCLU | Cytoplasm, mitochondria | Stress response — context-dependent |
The balance between sCLU and nCLU/iCLU determines whether clusterin exerts neuroprotective or pro-apoptotic effects. AD risk alleles are associated with reduced sCLU expression and enhanced inflammatory profiles ([May & Bhatt, 2023](https://doi.org/10.3389/fnagi.2023.1167886)).
Clusterin is one of the few known extracellular chaperones, functionally analogous to intracellular small heat shock proteins. It binds to non-native, misfolded, or aggregation-prone proteins and maintains them in a soluble state suitable for subsequent processing ([Wyatt et al., 2009](https://doi.org/10.1016/j.jmb.2009.04.061)):
Clusterin is a potent inhibitor of the terminal complement cascade:
As Apolipoprotein J, clusterin participates in lipid metabolism in the CNS:
Clusterin is intimately linked to multiple aspects of AD pathogenesis:
Genetic Risk: GWAS identified CLU as one of the top risk loci for late-onset AD. Key risk SNPs include rs11136000, rs11787077, rs2279590, and rs9331888. [The minor alleles of rs11136000 and rs11787077 are protective, being less frequent in AD patients ([Harold et al., 2009](https://doi.org/10.1038/ng.440)). CLU risk variants are associated with reduced plasma clusterin levels, lower white matter integrity, and faster cognitive decline.
[amyloid-beta](/proteins/amyloid-beta) Interaction: Clusterin is a major [Amyloid-Beta](/proteins/amyloid-beta)-binding protein in CSF and plasma:
Lipid Metabolism: CLU protective variants modulate neuronal excitability through lipid-droplet-mediated neuron-glia communication. Neuronal clusterin promotes lipid droplet formation in [astrocytes](/cell-types/astrocytes), which may buffer lipotoxic stress ([Jin et al., 2025](https://doi.org/10.1186/s13024-025-00840-1)).
A small molecule secreted clusterin enhancer has been identified that improves memory in AD mouse models by increasing sCLU levels and reducing Aβ burden ([Qi et al., 2025](https://doi.org/10.1038/s44386-025-00009-2)). This approach leverages the protective chaperone function of sCLU.
The study of Clusterin (Clu Apolipoprotein J) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving Clusterin (CLU / Apolipoprotein J) discovered through SciDEX knowledge graph analysis: